Vertex Pharmaceuticals management check

VRTX · Health Care · Biotechnology · CEO Reshma Kewalramani

Filings as of

81
Management score, ranked 50th of 487 · 5th of 60 in Health Care6 good · 1 to watch · 0 flaggedStrongest: owner returns · Weakest: skin in the game · Best and worst run in Health Care →

The seven checks

  • Good

    Have owners done well?

    Beat its chosen peersOwners$192Peers$125

    What $100 became since fiscal 2021

    100100th
    Detail

    $100 invested at the start of fiscal 2021 grew to $192, against $125 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20212025

    Pay actually paid $100 value, each on its own scale

    9585th
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.91 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Good

    What does the CEO cost owners?

    0.5% of net income

    $21.1m pay · $4.0bn net income, FY2025

    0.1%1%3%10%
    7375th
    Detail

    $21.1m of reported pay in fiscal 2025, against $4.0bn of net income.

  • Watch

    Do they own the stock?

    CEO stake ≈ 2.2 years of pay

    86,471 shares ≈ $46.0m

    0.1y1y5y20y100y

    6 mo: ▲ $0 bought · ▼ $22.0m sold

    5257th
    Detail

    The CEO holds 86,471 shares, directly or through trusts (unvested awards not counted): about 2.2 years of pay. Light activity: no buys, $22.0m sold in six months. 13 of 13 sales ran on pre-arranged 10b5-1 plans.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 260m2025 · 258m

    Diluted shares −0.5% a year; flagged above +2%

    0%10%20%

    Stock pay 5.7% of revenue

    5643rd
    Detail

    Diluted shares changed -0.5% a year over the last three fiscal years. Stock-based pay was 5.7% of revenue in the latest year.

  • Good

    Is leadership stable?

    7 leadership filings in 3 years

    7 filings under 8-K 5.02 in 3 years

    0101420+

    CEO: Reshma Kewalramani

    9069th
    Detail

    CEO in the pay table: Reshma Kewalramani. 7 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed April 2, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
$0$22.1m$44.2m$10020212022202320242025$192$125

Pay tied most to net product revenue

Other key measuresNet Product RevenuePipeline Progression(1)Adjusted Non-GAAP EBITDA(2)

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Reshma Kewalramani$21.1m$38.2m$7.7m$192$125$4.0bn
2024Reshma Kewalramani$21.5m$43.6m$8.1m$170$93−$500.0m
2023Reshma Kewalramani$20.6m$44.2m$7.4m$172$94$3.6bn
2022Reshma Kewalramani$15.9m$29.5m$9.0m$122$90$3.3bn
2021Reshma Kewalramani$15.2m$18.3m$7.2m$93$100$2.3bn

Insiders and the CEO's stakeQuiet

CEO & President
Reshma Kewalramani
Shares held
86,471
At that filing's price
≈ $46.0m
Latest Form 4
Nov 6, 2026

Light activity: no buys, $22.0m sold in six months. 13 of 13 sales ran on pre-arranged 10b5-1 plans.

Open-market trades by officers and directors since May 21, 2026.

  • SoldCharles F Jr WagnerEVP, CO & FO · 10b5-1 plan$8.4mNov 12, 2026
  • SoldReshma KewalramaniCEO & President · 10b5-1 plan$6.3mNov 6, 2026
  • SoldCarmen BozicEVP and CMO · 10b5-1 plan$4.3mJun 26, 2026
  • SoldDuncan McKechnieEVP, Chief Commercial Officer · 10b5-1 plan$800kJul 2, 2026

Leadership and governance on file

20222023202420252026Leadership 8Votes 5
All 8 filings

Latest shareholder vote results: May 13, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $5.0bn returned to owners in buybacks and dividends, 40% of net income, and $2.9bn of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
−$535.6m$1.7bn$4.0bn20212022202320242025Shares260m259m261m258m258m
Show the figures
Fiscal year20212022202320242025
Revenue$7.6bn$8.9bn$9.9bn$11.0bn$12.0bn
Net income$2.3bn$3.3bn$3.6bn−$535.6m$4.0bn
Stock-based pay$441.4m$491.3m$581.2m$698.5m$685.9m
Buybacks$1.4bn$0$427.6m$1.2bn$2.0bn
Dividends—————
Diluted shares260m259m261m258m258m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.